rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2004-6-15
|
pubmed:abstractText |
Adult Still's disease is a systemic inflammatory disorder of unknown etiology. First-line treatment for Still's disease includes nonsteroidal anti-inflammatory drugs and corticosteroids. In refractory cases o when the dose of corticosteroid is unacceptably high, other disease modifying antirheumatic drugs have been used. But recent study showed the efficacy anti-TNF therapy in adult Sill's disease refractory to conventional therapy. We report a favourable response to infliximab in two patients who has proved resistant to conventional therapy.
|
pubmed:language |
spa
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0212-7199
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
23-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15195482-Adrenal Cortex Hormones,
pubmed-meshheading:15195482-Adult,
pubmed-meshheading:15195482-Anti-Inflammatory Agents,
pubmed-meshheading:15195482-Antibodies, Monoclonal,
pubmed-meshheading:15195482-Drug Evaluation,
pubmed-meshheading:15195482-Drug Resistance,
pubmed-meshheading:15195482-Drug Therapy, Combination,
pubmed-meshheading:15195482-Female,
pubmed-meshheading:15195482-Humans,
pubmed-meshheading:15195482-Immunosuppressive Agents,
pubmed-meshheading:15195482-Methotrexate,
pubmed-meshheading:15195482-Remission Induction,
pubmed-meshheading:15195482-Still's Disease, Adult-Onset,
pubmed-meshheading:15195482-Tumor Necrosis Factor-alpha
|
pubmed:year |
2004
|
pubmed:articleTitle |
[Infliximab (anti-TNF-alpha) treatment in patients with adult Still's disease. Experience in 2 cases].
|
pubmed:affiliation |
Servicio de Reumatología, Hospital Universitario La Paz, Paseo de la Castellana, 261, 28046 Madrid. magebo@eresmas.com
|
pubmed:publicationType |
Journal Article,
English Abstract,
Case Reports
|